Haisco Pharmaceutical Group Co. Ltd. has described bromodomain-containing protein 9 (BRD9) inhibitors or BRD9 degradation inducers reported to be useful for the treatment of cancer.
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have divulged fused benzoisoxazolyl compounds acting as histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
Researchers from Duke University presented the discovery and preclinical evaluation of [211At]YF-2, a next-generation prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical.
Maxcyte Inc. and Vittoria Biotherapeutics Inc. have signed a strategic platform license agreement for use of Maxcyte’s Flow Electroporation technology and Expert platform by Vittoria Biotherapeutics. Under the agreement, Vittoria will obtain nonexclusive clinical and commercial rights to use Maxcyte’s Flow Electroporation technology and Expert platform, and will pay Maxcyte platform licensing fees and program-related revenue.
Beigene Co. Ltd. and Duality Biologics (Suzhou) Co. Ltd. have signed an agreement for Beigene to acquire an exclusive option for a global clinical and commercial license to a preclinical antibody-drug conjugate (ADC) therapy for select solid tumors.
Hillstream Biopharma Inc. reported a strategic reprioritization of its pipeline to focus on advancing novel oncology assets with the greatest potential and strong competitive profiles for solid tumors.
In recent years, targeting c-Met/HGF has emerged as a relevant strategy in cancer treatment, and several compounds with this mechanism of action have reached the market. Researchers from the First Affiliated Hospital of Wenzhou Medical College and colleagues reported on the design and characterization of a novel series of 4-(4-amino phenoxy) picolinamide derivatives that led to the identification of [I] as the lead compound.
Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. and Hangzhou Hertz Pharmaceutical Co. Ltd. have described apoptosis regulator Bcl-2 wild-type, Bcl-2 (D103Y mutant) and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.
Oncobix Co. Ltd. has divulged novel heterocyclic-substituted pyrimidine derivatives acting as ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.
RSS
